Quantcast
Channel: | Biosimilars Law Blog
Browsing index pages (8 articles)
↧

AIFA publishes “Second Concept Paper” on biosimilars

On June 15, 2016, AIFA (the Italian Medicines Agency) published a “Second Concept Paper” on the use of biosimilars within the National Health System (NHS). The document is intended to start a...

View Article


Europe approves its first mAb biosimilar & FDA is handling 17 biosimilar INDs

Not surprising after the European Medicines Agency (EMA) positive opinion for two biosimilars to Remicade (infliximab) in June, the first of these was authorized in September.  Authorization of Remsima...

View Article


EMA releases a draft revision to the Biosimilars Guideline for public...

The European Medicines Agency (“EMA”) initiated a public consultation on a proposed revision of its Guideline on “Similar Biological Medicinal Products” (the “Biosimilars Guideline”), available at the...

View Article

EMA takes steps toward facilitating global clinical trials for biosimilars

Applicants for marketing authorisation for biosimilars in the European Union (“EU”), under certain conditions, will be able in the near future to use batches of reference biological medicinal products...

View Article

AIFA publishes “Second Concept Paper” on biosimilars

On June 15, 2016, AIFA (the Italian Medicines Agency) published a “Second Concept Paper” on the use of biosimilars within the National Health System (NHS). The document is intended to start a...

View Article


Europe approves its first mAb biosimilar & FDA is handling 17 biosimilar INDs

Not surprising after the European Medicines Agency (EMA) positive opinion for two biosimilars to Remicade (infliximab) in June, the first of these was authorized in September.  Authorization of Remsima...

View Article

EMA releases a draft revision to the Biosimilars Guideline for public...

The European Medicines Agency (“EMA”) initiated a public consultation on a proposed revision of its Guideline on “Similar Biological Medicinal Products” (the “Biosimilars Guideline”), available at the...

View Article

EMA takes steps toward facilitating global clinical trials for biosimilars

Applicants for marketing authorisation for biosimilars in the European Union (“EU”), under certain conditions, will be able in the near future to use batches of reference biological medicinal products...

View Article

Browsing index pages (8 articles)


Latest Images